Researchers dig into medical records to find who is at risk for dangerous side effect from breast cancer drug
NCT ID NCT05709158
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at medical records from over 1,300 breast cancer patients in Japan who took the drug palbociclib. The goal was to find out which patients are more likely to develop a severe drop in white blood cells (grade 4 neutropenia), a known side effect. Researchers compared patients who had this side effect to those who did not, using statistical methods to identify risk factors. The study did not test a new treatment, but rather gathered information to help doctors better manage this risk.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
4,184 people
The number who actually took part.
- Started
-
Aug 2024
- Finished
-
Aug 2024
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Breast cancer patients treated with Palbociclib
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Having prescription records of palbociclib from 15 December 2017 to 29 February 2024. * Having any breast cancer records in same month as the first prescription date. Exclusion Criteria: * Having an ANC less than the threshold value for grade 4 neutropenia within 30 days of the first prescription of palbociclib * Having any records of anti-HER2 medication
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Breast cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pfizer New York
New York, New York, 10001, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a common steroid shield breast cancer patients from a dangerous drug side effect?
- Tiny magnetic seeds could guide surgeons to the right lymph node
- New PET tracer aims to light up hidden cancer targets
- Gut bacteria supplement tested against chemo hair loss
- Can a mindfulness program boost Self-Compassion in breast cancer survivors?
- Can a Decades-Old Anti-Inflammatory drug quiet the joint pain that drives women off breast cancer therapy?